Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2023, versus the comparable prior-year period, as follows:

Consolidated operating results:

Revenue increased 4.2% to $554 million
GAAP Diluted Earnings-per-Share (EPS) of $3.51
Adjusted Diluted EPS of $4.71, a decrease of 2.7%

VITAS segment operating results:

Net Patient Revenue of $321 million, an increase of 7.8%
Average Daily Census (ADC) of 18,392, an increase of 6.2%
Admissions of 15,611, an increase of 5.9%
Net Income, excluding certain discrete items, of $35.7 million, an increase of 1.3%
Adjusted EBITDA, excluding Medicare Cap, of $50.7 million, an increase of 1.4%
Adjusted EBITDA margin, excluding Medicare Cap, of 15.7%, a decline of 101-basis points

Roto-Rooter segment operating results:

Revenue of $233 million, a decline of 0.2%
Net Income, excluding certain discrete items, of $46.1 million, an decrease of 5.6%
Adjusted EBITDA of $65.9 million, a decline of 4.5%
Adjusted EBITDA margin of 28.3%, a decline of 128-basis points

VITAS

VITAS net revenue was $321 million in the second quarter of 2023, which is an increase of 7.8% when compared to the prior year period. This revenue increase is comprised primarily of a 6.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.7%, partially offset by 100-basis points as a result of CMS reimplementing sequestration that was suspended at the start of the pandemic. Acuity mix shift had minimal impact in the quarter when compared to the prior-year revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes negatively impacted revenue growth by 10-basis points.

In the second quarter of 2023, VITAS accrued $2.75 million in Medicare Cap billing limitations. This compares to a $2.0 million Medicare Cap billing limitation in the second quarter of 2022.

Of VITAS' 30 Medicare provider numbers, 24 provider numbers have a trailing nine-month Medicare Cap cushion of 10% or greater, three provider numbers have a cushion between 5% and 10%, and three provider numbers have a trailing nine-month billing limitation liability.

Average revenue per patient per day in the second quarter of 2023 was $197.02 which is 178-basis points above the prior-year period. Reimbursement for routine home care and high acuity care averaged $172.91 and $1,031.58, respectively. During the quarter, high acuity days-of-care were 2.8% of total days of care, essentially equal to the prior-year quarter.

The second quarter 2023 gross margin, excluding Medicare Cap and the hiring and retention bonus program, was 22.7%. This is a 143-basis point increase when compared to the second quarter of 2022. The margin increase is net of sequestration which reduced reimbursement 100-basis points when compared to the prior year. During the quarter, VITAS increased the licensed healthcare staff by 309 professionals. This results in total licensed staff increasing by 784 professionals since the inception of the retention program on July 1, 2022. The increase of 309 net professionals hired during the second quarter of 2023, basically underutilized capacity, is estimated to have negatively impacted margins in the quarter by approximately 80-basis points.

Selling, general and administrative expenses were $22.7 million in the second quarter of 2023 and compares to $23.1 million incurred in the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap, totaled $50.7 million in the quarter, an increase of 1.4%. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 15.7%, which is 101-basis points below the prior-year period. This Adjusted EBITDA margin was negatively impacted by 100-basis points for the reimplementation of sequestration and approximately 80-basis points due to the addition of 309 licensed professionals during the second quarter of 2023.

Roto-Rooter

Roto-Rooter generated quarterly revenue of $233 million in the second quarter of 2023, a decline of 0.2%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $55.5 million, an increase of 1.3%, over the prior year. This aggregate commercial revenue growth consisted of drain cleaning revenue declining 3.0%, plumbing increasing 5.4%, excavation increasing 2.9%, and water restoration increasing 9.7%.

Roto-Rooter branch residential revenue in the quarter totaled $158 million, a decline of 1.1%, over the prior-year period. This aggregate residential revenue growth consisted of drain cleaning decreasing 8.6%, plumbing declining 2.8%, excavation expanding 3.8%, and water restoration increasing 2.5%.

Roto-Rooter's gross margin in the quarter was 52.3%, an 89-basis point decline when compared to the second quarter of 2022. Adjusted EBITDA in the second quarter of 2023 totaled $65.9 million, a decrease of 4.5%. The Adjusted EBITDA margin in the quarter was 28.3%, which is 128-basis points below the prior year period.

Chemed Consolidated

As of June 30, 2023, Chemed had total cash and cash equivalents of $160 million and no current or long-term debt.

In June 2022, Chemed entered into a five-year $550 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consisted of a $100 million amortizable term loan and a $450 million revolving credit facility. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. During the quarter, the Company paid off the remaining portion of the term loan. The Company has approximately $405 million of undrawn borrowing capacity under the Credit Agreement.

During the quarter, the Company repurchased 25,000 shares of Chemed stock for $13.4 million which equates to a cost per share of $536.98. As of June 30, 2023, there was approximately $74 million of remaining share repurchase authorization under its plan.

Guidance for 2023

VITAS 2023 revenue, prior to Medicare Cap, is estimated to increase 8.5% to 9.5% when compared to 2022. Forecasted revenue growth is negatively impacted by 75-basis points as a result of the sequestration relief in the first half of 2022 compared to a full year of sequestration in 2023. ADC is estimated to increase 6.5% to 7.5%. Full year adjusted EBITDA margin, prior to Medicare Cap and accrued retention bonuses related to the hiring initiatives, is estimated to be 16.5% to 17.0%. We are currently estimating $11 million for Medicare Cap billing limitations in calendar year 2023.

Roto-Rooter is forecasted to achieve full-year 2023 revenue growth of 1.0% to 2.0%. Roto-Rooter's adjusted EBITDA margin for 2023 is expected to be 28.0% to 28.5%.

Based upon the above, full-year 2023 earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, retention program for licensed healthcare employees, and other discrete items, is estimated to be in the range of $19.90 to $20.10. Current 2023 guidance assumes an effective corporate tax rate on adjusted earnings of 24.7% and a diluted share count of 15.2 million shares. Chemed's 2022 reported adjusted earnings per diluted share was $19.75.

Conference Call

Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday July 27, 2023, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/ntafx2iw.

Participants may also register via teleconference at: https://register.vevent.com/register/BI8193ef2f50f34636bd3182c2d88daff9. Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website.

Chemed Corporation operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to approximately 18,400 patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed's financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company's operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed's management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed's management to estimate the resources required to meet Chemed's future financial obligations and expenditures. Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed's net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

Forward-Looking Statements

Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.

These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed's dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed's most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Service revenues and sales	$	553,816		$	531,288			1,113,973		$	1,061,837
Cost of services provided and goods sold		374,193			336,821			744,898			673,373
Selling, general and administrative expenses (aa)		94,987			87,853			195,082			177,807
Depreciation		12,634			12,714			24,920			24,852
Amortization		2,514			2,520			5,027			5,038
Other operating (income)/expense		(18	)		(558	)		1,721			(545	)
Total costs and expenses		484,310			439,350			971,648			880,525
Income from operations		69,506			91,938			142,325			181,312
Interest expense		(771	)		(902	)		(2,322	)		(1,712	)
Other income/(expense)--net (bb)		1,609			(4,930	)		1,506			(8,792	)
Income before income taxes		70,344			86,106			141,509			170,808
Income taxes		(16,967	)		(19,650	)		(34,011	)		(40,183	)
Net income	$	53,377		$	66,456		$	107,498		$	130,625
Earnings Per Share
Net income	$	3.54		$	4.45		$	7.16		$	8.73
Average number of shares outstanding		15,058			14,932			15,013			14,959
Diluted Earnings Per Share
Net income	$	3.51		$	4.40		$	7.09		$	8.62
Average number of shares outstanding		15,219			15,111			15,167			15,152

(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
SG&A expenses before long-term incentive compensation
and the impact of market value adjustments related to
deferred compensation plans	$	91,733		$	91,422		$	189,634		$	184,000
Long-term incentive compensation		1,750			1,517			4,264			2,827
Market value adjustments related to deferred
compensation trusts		1,504			(5,086	)		1,184			(9,020	)
Total SG&A expenses	$	94,987		$	87,853		$	195,082		$	177,807

(bb) Other income/(expense)--net comprises (in thousands):
	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Market value adjustments related to deferred
compensation trusts	$	1,504		$	(5,086	)	$	1,184		$	(9,020	)
Interest income		113			154			263			226
Other		(8	)		2			59			2
Total other income/(expense)--net	$	1,609		$	(4,930	)	$	1,506		$	(8,792	)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)

	June 30,
	2023			2022
Assets
Current assets
Cash and cash equivalents	$	159,924		$	9,640
Accounts receivable less allowances		120,314			136,555
Inventories		11,684			10,696
Prepaid income taxes		16,666			17,256
Prepaid expenses		28,572			28,999
Total current assets		337,160			203,146
Investments of deferred compensation plans held in trust		99,522			96,061
Properties and equipment, at cost less accumulated depreciation		208,101			192,005
Lease right of use asset		127,215			128,290
Identifiable intangible assets less accumulated amortization		94,932			103,837
Goodwill		581,542			579,653
Other assets		56,708			9,972
Total Assets	$	1,505,180		$	1,312,964
Liabilities
Current liabilities
Accounts payable	$	41,058		$	73,975
Current portion of long-term debt		-			5,000
Accrued insurance		57,461			54,828
Accrued compensation		74,384			68,290
Accrued legal		6,096			808
Short-term lease liability		38,779			39,062
Other current liabilities		84,709			43,105
Total current liabilities		302,487			285,068
Deferred income taxes		36,681			21,054
Long-term debt		-			111,800
Deferred compensation liabilities		98,941			95,624
Long-term lease liability		102,112			103,389
Other liabilities		12,880			11,069
Total Liabilities		553,101			628,004
Stockholders' Equity
Capital stock		36,996			36,651
Paid-in capital		1,240,415			1,089,129
Retained earnings		2,294,004			2,090,214
Treasury stock, at cost		(2,621,657	)		(2,533,306	)
Deferred compensation payable in Company stock		2,321			2,272
Total Stockholders' Equity		952,079			684,960
Total Liabilities and Stockholders' Equity	$	1,505,180		$	1,312,964

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)

	For the Six Months Ended June 30,
	2023			2022
Cash Flows from Operating Activities
Net income	$	107,498		$	130,625
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization		29,947			29,890
Stock option expense		16,882			14,667
Noncash long-term incentive compensation		3,493			2,497
Benefit for deferred income taxes		(1,932	)		(2,129	)
Noncash directors' compensation		1,444			1,170
Amortization of debt issuance costs		420			153
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Decrease in accounts receivable		20,100			887
Increase in inventories		(1,412	)		(587	)
Decrease in prepaid expenses		1,719			3,689
Increase/(decrease) in accounts payable and
other current liabilities		8,561			(24,001	)
Change in current income taxes		1,865			27
Net change in lease assets and liabilities		(1,046	)		705
(Increase)/decrease in other assets		(3,810	)		2,071
Increase/(decrease) in other liabilities		7,344			(1,491	)
Other sources/(uses)		1,736			(503	)
Net cash provided by operating activities		192,809			157,670
Cash Flows from Investing Activities
Capital expenditures		(33,420	)		(25,610	)
Proceeds from sale of fixed assets		360			1,757
Business combinations, net of cash acquired		(305	)		(1,650	)
Other uses		(169	)		(132	)
Net cash used by investing activities		(33,534	)		(25,635	)
Cash Flows from Financing Activities
Payments on other long-term debt		(97,500	)		-
Proceeds from other long-term debt		-			100,000
Proceeds from exercise of stock options		53,675			12,869
Purchases of treasury stock		(13,425	)		(77,214	)
Dividends paid		(11,412	)		(10,722	)
Capital stock surrendered to pay taxes on stock-based compensation		(5,313	)		(12,115	)
Debt issuance costs		-			(1,510	)
Payments on revolving line of credit		-			(263,300	)
Proceeds from revolving line of credit		-			95,100
Change in cash overdrafts payable		-			1,716
Other sources/(uses)		498			(114	)
Net cash used by financing activities		(73,477	)		(155,290	)
Increase/(decrease) in Cash and Cash Equivalents		85,798			(23,255	)
Cash and cash equivalents at beginning of year		74,126			32,895
Cash and cash equivalents at end of year	$	159,924		$	9,640

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022
(in thousands)(unaudited)
										Chemed
	VITAS			Roto-Rooter			Corporate			Consolidated
2023 (a)
Service revenues and sales	$	320,861		$	232,955		$	-		$	553,816
Cost of services provided and goods sold		263,085			111,108			-			374,193
Selling, general and administrative expenses		22,656			56,012			16,319			94,987
Depreciation		4,940			7,681			13			12,634
Amortization		26			2,488			-			2,514
Other operating expense/(income)		26			(44	)		-			(18	)
Total costs and expenses		290,733			177,245			16,332			484,310
Income/(loss) from operations		30,128			55,710			(16,332	)		69,506
Interest expense		(51	)		(124	)		(596	)		(771	)
Intercompany interest income/(expense)		4,810			2,869			(7,679	)		-
Other income—net		70			35			1,504			1,609
Income/(loss) before income taxes		34,957			58,490			(23,103	)		70,344
Income taxes		(8,829	)		(14,116	)		5,978			(16,967	)
Net income/(loss)	$	26,128		$	44,374		$	(17,125	)	$	53,377

2022 (b)
Service revenues and sales	$	297,781		$	233,507		$	-		$	531,288
Cost of services provided and goods sold		227,533			109,288			-			336,821
Selling, general and administrative expenses		23,148			54,982			9,723			87,853
Depreciation		6,062			6,634			18			12,714
Amortization		26			2,494			-			2,520
Other operating expense/(income)		(807	)		249			-			(558	)
Total costs and expenses		255,962			173,647			9,741			439,350
Income/(loss) from operations		41,819			59,860			(9,741	)		91,938
Interest expense		(44	)		(115	)		(743	)		(902	)
Intercompany interest income/(expense)		4,683			2,205			(6,888	)		-
Other income/(expense)—net		119			37			(5,086	)		(4,930	)
Income/(loss) before income taxes		46,577			61,987			(22,458	)		86,106
Income taxes		(11,365	)		(14,915	)		6,630			(19,650	)
Net income/(loss)	$	35,212		$	47,072		$	(15,828	)	$	66,456


The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(in thousands)(unaudited)

										Chemed
	VITAS			Roto-Rooter			Corporate			Consolidated
2023 (a)
Service revenues and sales	$	631,339		$	482,634		$	-		$	1,113,973
Cost of services provided and goods sold		516,739			228,159			-			744,898
Selling, general and administrative expenses		45,992			116,825			32,265			195,082
Depreciation		9,898			14,994			28			24,920
Amortization		52			4,975			-			5,027
Other operating expense		38			1,683			-			1,721
Total costs and expenses		572,719			366,636			32,293			971,648
Income/(loss) from operations		58,620			115,998			(32,293	)		142,325
Interest expense		(102	)		(257	)		(1,963	)		(2,322	)
Intercompany interest income/(expense)		9,458			5,612			(15,070	)		-
Other income—net		259			64			1,183			1,506
Income/(loss) before income taxes		68,235			121,417			(48,143	)		141,509
Income taxes		(17,343	)		(29,390	)		12,722			(34,011	)
Net income/(loss)	$	50,892		$	92,027		$	(35,421	)	$	107,498

2022 (b)
Service revenues and sales	$	596,970		$	464,867		$	-		$	1,061,837
Cost of services provided and goods sold		454,773			218,600			-			673,373
Selling, general and administrative expenses		45,600			111,937			20,270			177,807
Depreciation		11,613			13,203			36			24,852
Amortization		49			4,989			-			5,038
Other operating expense		(955	)		410			-			(545	)
Total costs and expenses		511,080			349,139			20,306			880,525
Income/(loss) from operations		85,890			115,728			(20,306	)		181,312
Interest expense		(96	)		(229	)		(1,387	)		(1,712	)
Intercompany interest income/(expense)		9,339			4,381			(13,720	)		-
Other income—net		156			72			(9,020	)		(8,792	)
Income/(loss) before income taxes		95,289			119,952			(44,433	)		170,808
Income taxes		(23,595	)		(28,943	)		12,355			(40,183	)
Net income/(loss)	$	71,694		$	91,009		$	(32,078	)	$	130,625


The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022
(in thousands)(unaudited)
										Chemed
	VITAS			Roto-Rooter			Corporate			Consolidated
2023
Net income/(loss)	$	26,128		$	44,374		$	(17,125	)	$	53,377
Add/(deduct):
Interest expense		51			124			596			771
Income taxes		8,829			14,116			(5,978	)		16,967
Depreciation		4,940			7,681			13			12,634
Amortization		26			2,488			-			2,514
EBITDA		39,974			68,783			(22,494	)		86,263
Add/(deduct):
Intercompany interest expense/(income)		(4,810	)		(2,869	)		7,679			-
Interest income		(79	)		(34	)		-			(113	)
Licensed healthcare retention bonus		12,833			-			-			12,833
Stock option expense		-			-			8,400			8,400
Long-term incentive compensation		-			-			1,750			1,750
Adjusted EBITDA	$	47,918		$	65,880		$	(4,665	)	$	109,133

2022
Net income/(loss)	$	35,212		$	47,072		$	(15,828	)	$	66,456
Add/(deduct):
Interest expense		44			115			743			902
Income taxes		11,365			14,915			(6,630	)		19,650
Depreciation		6,062			6,634			18			12,714
Amortization		26			2,494			-			2,520
EBITDA		52,709			71,230			(21,697	)		102,242
Add/(deduct):
Intercompany interest expense/(income)		(4,683	)		(2,205	)		6,888			-
Interest income		(118	)		(37	)		1			(154	)
Stock option expense		-			-			7,216			7,216
Long-term incentive compensation		-			-			1,517			1,517
Medicare cap sequestration adjustment		138			-			-			138
Direct costs related to COVID-19		(80	)		-			-			(80	)
Other		-			28			-			28
Adjusted EBITDA	$	47,966		$	69,016		$	(6,075	)	$	110,907

The "Footnotes to Financial Statements" are integral parts of this financial information.


CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(in thousands)(unaudited)
										Chemed
	VITAS			Roto-Rooter			Corporate			Consolidated
2023
Net income/(loss)	$	50,892		$	92,027		$	(35,421	)	$	107,498
Add/(deduct):
Interest expense		102			257			1,963			2,322
Income taxes		17,343			29,390			(12,722	)		34,011
Depreciation		9,898			14,994			28			24,920
Amortization		52			4,975			-			5,027
EBITDA		78,287			141,643			(46,152	)		173,778
Add/(deduct):
Intercompany interest expense/(income)		(9,458	)		(5,612	)		15,070			-
Interest income		(199	)		(64	)		-			(263	)
Licensed healthcare retention bonus		23,750			-			-			23,750
Stock option expense		-			-			16,882			16,882
Long-term incentive compensation		-			-			4,264			4,264
Litigation settlements		-			1,756			-			1,756
Adjusted EBITDA	$	92,380		$	137,723		$	(9,936	)	$	220,167
2022
Net income/(loss)	$	71,694		$	91,009		$	(32,078	)	$	130,625
Add/(deduct):
Interest expense		96			229			1,387			1,712
Income taxes		23,595			28,943			(12,355	)		40,183
Depreciation		11,613			13,203			36			24,852
Amortization		49			4,989			-			5,038
EBITDA		107,047			138,373			(43,010	)		202,410
Add/(deduct):
Intercompany interest expense/(income)		(9,339	)		(4,381	)		13,720			-
Interest income		(155	)		(71	)		-			(226	)
Stock option expense		-			-			14,667			14,667
Long-term incentive compensation		-			-			2,827			2,827
Direct costs related to COVID-19		310			960			-			1,270
Medicare cap sequestration adjustment		138			-			-			138
Other		-			28			-			28
Adjusted EBITDA	$	98,001		$	134,909		$	(11,796	)	$	221,114

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Net income as reported	$	53,377		$	66,456		$	107,498		$	130,625
Add/(deduct) pre-tax cost of:
Licensed healthcare worker retention bonus		12,833			-			23,750			-
Stock option expense		8,400			7,216			16,882			14,667
Amortization of reacquired franchise agreements		2,352			2,352			4,704			4,704
Long-term incentive compensation		1,750			1,517			4,264			2,827
Litigation settlements		-			-			1,756			-
Medicare cap sequestration adjustment		-			138			-			138
Other		-			28			-			28
Direct costs related to COVID-19		-			(80	)		-			1,270
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1)		(5,525	)		(2,038	)		(11,151	)		(4,449	)
Excess tax benefits on stock compensation		(1,501	)		(2,499	)		(3,150	)		(3,940	)
Adjusted net income	$	71,686		$	73,090		$	144,553		$	145,870

Diluted Earnings Per Share As Reported
Net income	$	3.51		$	4.40		$	7.09		$	8.62
Average number of shares outstanding		15,219			15,111			15,167			15,152

Adjusted Diluted Earnings Per Share
Adjusted net income	$	4.71		$	4.84		$	9.53		$	9.63
Average number of shares outstanding		15,219			15,111			15,167			15,152

(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)

	Three Months Ended June 30,								Six Months Ended June 30,
OPERATING STATISTICS	2023				2022				2023				2022
Net revenue ($000) (c)
Homecare	$	278,116			$	257,631			$	545,166			$	515,267
Inpatient		27,401				24,619				56,494				51,189
Continuous care		21,081				19,538				41,022				39,116
Other		3,154				3,213				6,175				6,220
Subtotal	$	329,752			$	305,001			$	648,857			$	611,792
Room and board, net		(2,904	)			(2,166	)			(5,672	)			(4,283	)
Contractual allowances		(3,237	)			(3,054	)			(6,346	)			(6,039	)
Medicare cap allowance		(2,750	)			(2,000	)			(5,500	)			(4,500	)
Net Revenue	$	320,861			$	297,781			$	631,339			$	596,970
Net revenue as a percent of total before Medicare cap allowance
Homecare		84.3		%		84.5		%		84.0		%		84.2		%
Inpatient		8.3				8.1				8.7				8.4
Continuous care		6.4				6.4				6.3				6.4
Other		1.0				1.0				1.0				1.0
Subtotal		100.0				100.0				100.0				100.0
Room and board, net		(0.8	)			(0.7	)			(0.9	)			(0.7	)
Contractual allowances		(1.0	)			(1.0	)			(1.0	)			(1.0	)
Medicare cap allowance		(0.8	)			(0.7	)			(0.8	)			(0.7	)
Net Revenue		97.4		%		97.6		%		97.3		%		97.6		%
Days of care
Homecare		1,340,655				1,266,604				2,627,092				2,525,276
Nursing home		279,898				259,046				545,327				507,514
Respite		6,159				6,095				11,919				11,463
Subtotal routine homecare and respite		1,626,712				1,531,745				3,184,338				3,044,253
Inpatient		25,125				23,155				51,494				47,742
Continuous care		21,873				20,802				42,559				41,884
Total		1,673,710				1,575,702				3,278,391				3,133,879

Number of days in relevant time period		91				91				181				181
Average daily census ("ADC") (days)
Homecare		14,732				13,918				14,514				13,952
Nursing home		3,076				2,847				3,013				2,804
Respite		68				67				66				63
Subtotal routine homecare and respite		17,876				16,832				17,593				16,819
Inpatient		276				254				286				264
Continuous care		240				229				235				231
Total		18,392				17,315				18,114				17,314
Total Admissions		15,611				14,735				31,790				31,265
Total Discharges		15,104				14,603				30,509				31,465
Average length of stay (days)		99.5				103.7				99.7				104.3
Median length of stay (days)		16.0				17.0				15.0				16.0
ADC by major diagnosis
Cerebro		41.9		%		37.6		%		42.0		%		37.5		%
Neurological		18.8				22.7				19.0				22.8
Cancer		10.8				11.2				10.6				11.2
Cardio		16.1				15.8				16.0				15.8
Respiratory		7.1				7.2				7.2				7.3
Other		5.3				5.5				5.2				5.4
Total		100.0		%		100.0		%		100.0		%		100.0		%
Admissions by major diagnosis
Cerebro		25.9		%		23.8		%		26.2		%		23.4		%
Neurological		10.1				13.0				10.4				12.9
Cancer		27.1				27.3				25.9				26.0
Cardio		16.3				15.4				16.3				14.7
Respiratory		9.8				9.9				10.4				10.6
Other		10.8				10.6				10.8				12.4
Total		100.0		%		100.0		%		100.0		%		100.0		%

Estimated uncollectible accounts as a percent of revenues		1.0		%		1.0		%		1.0		%		1.0		%

Accounts receivable --
Days of revenue outstanding-excluding unapplied Medicare payments		35.2				33.7				n.a.				n.a.
Days of revenue outstanding-including unapplied Medicare payments		22.6				28.2				n.a.				n.a.

The "Footnotes to Financial Statements" are integral parts of this financial information.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022
(unaudited)

(a)	Included in the results of operations for 2023 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended June 30, 2023
		VITAS			Roto-Rooter			Corporate			Consolidated

	Licensed healthcare worker retention bonus	$	(12,833	)	$	-		$	-		$	(12,833	)
	Stock option expense		-			-			(8,400	)		(8,400	)
	Amortization of reacquired franchise agreements		-			(2,352	)		-			(2,352	)
	Long-term incentive compensation		-			-			(1,750	)		(1,750	)
	Pretax impact on earnings		(12,833	)		(2,352	)		(10,150	)		(25,335	)
	Excess tax benefits on stock compensation		-			-			1,501			1,501
	Income tax benefit on the above		3,259			623			1,643			5,525
	After-tax impact on earnings	$	(9,574	)	$	(1,729	)	$	(7,006	)	$	(18,309	)

		Six Months Ended June 30, 2023
		VITAS			Roto-Rooter			Corporate			Consolidated

	Licensed healthcare worker retention bonus	$	(23,750	)	$	-		$	-		$	(23,750	)
	Stock option expense		-			-			(16,882	)		(16,882	)
	Amortization of reacquired franchise agreements		-			(4,704	)		-			(4,704	)
	Long-term incentive compensation		-			-			(4,264	)		(4,264	)
	Litigation settlements		-			(1,756	)		-			(1,756	)
	Pretax impact on earnings		(23,750	)		(6,460	)		(21,146	)		(51,356	)
	Excess tax benefits on stock compensation		-			-			3,150			3,150
	Income tax benefit on the above		6,033			1,712			3,406			11,151
	After-tax impact on earnings	$	(17,717	)	$	(4,748	)	$	(14,590	)	$	(37,055	)

(b)	Included in the results of operations for 2022 are the following significant credits/(charges) which may not be indicative of ongoing operations
	(in thousands):
		Three Months Ended June 30, 2022
		VITAS			Roto-Rooter			Corporate			Consolidated

	Stock option expense	$	-		$	-		$	(7,216	)	$	(7,216	)
	Amortization of reacquired franchise agreements		-			(2,352	)		-			(2,352	)
	Long-term incentive compensation		-			-			(1,517	)		(1,517	)
	Medicare cap sequestration adjustment		(138	)		-			-			(138	)
	Direct costs related to COVID-19		80			-			-			80
	Other		-			(28	)		-			(28	)
	Pretax impact on earnings		(58	)		(2,380	)		(8,733	)		(11,171	)
	Excess tax benefits on stock compensation		-			-			2,499			2,499
	Income tax benefit on the above		15			631			1,392			2,038
	After-tax impact on earnings	$	(43	)	$	(1,749	)	$	(4,842	)	$	(6,634	)

		Six Months Ended June 30, 2022
		VITAS			Roto-Rooter			Corporate			Consolidated

	Stock option expense	$	-		$	-		$	(14,667	)	$	(14,667	)
	Amortization of reacquired franchise agreements		-			(4,704	)		-			(4,704	)
	Long-term incentive compensation		-			-			(2,827	)		(2,827	)
	Direct costs related to COVID-19		(310	)		(960	)		-			(1,270	)
	Medicare cap sequestration adjustment		(138	)		-			-			(138	)
	Other		-			(28	)		-			(28	)
	Pretax impact on earnings		(448	)		(5,692	)		(17,494	)		(23,634	)
	Excess tax benefits on stock compensation		-			-			3,940			3,940
	Income tax benefit on the above		114			1,508			2,827			4,449
	After-tax impact on earnings	$	(334	)	$	(4,184	)	$	(10,727	)	$	(15,245	)

(c)	VITAS has 10 large (greater than 450 ADC), 18 medium (greater than 200 but less than 450 ADC) and 22 small (less than 200 ADC) hospice programs. Of Vitas' 30 Medicare provider numbers, for the current cap year, 24 provider numbers have a Medicare cap cushion of greater than 10%, three provider numbers have a Medicare cap cushion between 5% and 10% and three provider numbers have a Medicare cap liability.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230726455862/en/

Chemed Reports Second-Quarter 2023 Results